ClinicalTrials.gg
CompletedNCT07900282Updated Nov 2, 2026

Low-Dose Linperlisib Achieves Rapid Hematological Response in a Patient With Pure Red Cell Aplasia and Moderate-to-Severe Renal Insufficiency: A Case Report

An observational study in Linperlisib, PRCA and Moderate-to-Severe Renal Insufficiency, sponsored by Peking Union Medical College Hospital. Completed at 1 site in China. Open to male participants. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by Peking Union Medical College Hospital · Observational

Updated Nov 2, 2026Primary outcomes revisedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
1
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 61 studies in Renal Insufficiency with a site in China — 16 open to participants now, 16 under way, none of them phase 3. Renal Insufficiency · China.

Enrollment
13th of 13
1 · median 228
Started
2026
with 8 others
Observational
13 of 61
5 open now
Registered
57th of 61
by date

Among the 61 studies in Renal Insufficiency with a site in China, this one is the 13th largest by enrollment of the 13 observational ones that give a count, is one of 9 that started in 2026, is one of 13 observational ones, and was the 57th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

16 of the 61 studies in Renal Insufficiency with a site in China are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies in Renal Insufficiency with a site in China, or all of them as a file.
02

Study summary

This article reports a case of a 70-year-old male patient diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL)-associated pure red cell aplasia (PRCA) complicated by moderate-to-severe renal insufficiency. The patient was refractory or intolerant to multiple prior treatment lines, including cyclosporine A, tacrolimus plus prednisone, sirolimus, and cyclophosphamide, and was transfusion-dependent. In this case,we choose the low-dose linperlisib.

03

Conditions studied

  • Linperlisib
  • PRCA
  • Moderate-to-Severe Renal Insufficiency

Browse trials for

Keywords

  • linperlisib
  • PRCA
  • Moderate-to-Severe Renal Insufficiency
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

A 70-year-old male patient diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL)-associated pure red cell aplasia (PRCA) complicated by moderate-to-severe renal insufficiency

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • People who diagnosed with T-cell large granular lymphocytic leukemia (T-LGLL)-associated pure red cell aplasia (PRCA).
  • People who treatmented by linperlisib.

Exclusion criteria

Exclusion Criteria:

  • People who refuse to sign the form.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
1 participant (actual)
Patient registry
No

Interventions

06

What researchers measure

Primary outcomes

  1. hemoglobin

    unit of measure:concentration of HGB(g/L);measurement tool:physiological parameter(man≥120g/L,female≥110g/L)

    Time frame: 2、4、8weeks

07

Study locations

1 site
  • Peking Union Medical College Hospital
    Beijing, B 100730, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2026 to primary completion in Jan 2026, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2026
First posted
Oct 28, 2026
StartActual
Jan 31, 2026
Primary completionActual
Jan 31, 2026
CompletionActual
Jan 31, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary outcomes
1 description edited
What changed in the outcomes
  • Descriptionhemoglobin: how it is measured was reworded
Nov 2, 2026
Registered
First appeared on the registry
Oct 28, 2026
Show all 2 updates
  1. Nov 2, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • Descriptionhemoglobin: how it is measured was reworded
  2. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07900282
Responsible party
Chen Miao (Peking Union Medical College Hospital, Peking Union Medical College Hospital) — Principal investigator
First posted
Oct 28, 2026
Start date
Jan 31, 2026
Primary completion
Jan 31, 2026
Completion
Jan 31, 2026
Last update
Nov 2, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion